REG - AstraZeneca PLC - ASTRAZENECA COMPLETES DIVESTMENT OF CAPRELSA <Origin Href="QuoteRef">AZN.L</Origin>

AstraZenecaAnnouncement

07/10/2015 07:00

RNS Number : 4580B
AstraZeneca PLC
07 October 2015
ASTRAZENECA COMPLETES DIVESTMENT OF RARE DISEASE MEDICINE CAPRELSA
AstraZeneca has announcedtheglobal completion of the divestment ofCaprelsa (vandetanib), a rare disease medicine, to Genzyme, a Sanofi company. 
Genzyme made an upfront payment to AstraZeneca of $165 millionto acquire the global rights to sell and developCaprelsa, and will make further development and sales milestone payments of up to $135 million. The transaction does not include the transfer of any AstraZeneca employees or facilities.
The divestmentreinforces AstraZeneca's strategic focus on its three main therapy areas. As an asset divestment, the upfront receipt andany subsequent paymentsfor the agreementwill be reported in Other Operating Income in the Company's financial statements. The transaction does not impact AstraZeneca's financial guidance for 2015.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
CONTACTS
Media Enquiries


Esra Erkal-Paler
UK/Global
+44 20 7604 8030
Vanessa Rhodes
UK/Global
+44 20 7604 8037
Ayesha Bharmal
UK/Global
+44 20 7604 8034
Karen Birmingham
UK/Global
+44 20 7604 8120
Jacob Lund
Sweden
+46 8553260 20
Michele Meixell
US
+1 302 885 2677
Investor Enquiries



UK



Thomas Kudsk Larsen
Oncology
+44 20 7604 8199
+44 7818 524185
Eugenia Litz
RIA
+44 20 7604 8233
+44 7884 735627
Nick Stone
CVMD
+44 20 7604 8236
+44 7717 618834
Craig Marks
ING
+44 20 7604 8591
+44 7881 615764
Christer Gruvris

+44 20 7604 8126
+44 7827 836825
US



Lindsey Trickett
Oncology, ING
+1 301 398 5118
+1 240 543 7970
Mitch Chan
Oncology
+1 301 398 1849
+1 301 398 1849
Dial / Toll-Free

+1 301 398 3251
+1 866 381 7277
Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease, 
ING - Infection, Neuroscience and Gastrointestinal
7 October 2015
-ENDS-

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCEAEEKELKSFAF